5 min read
Therapeutic Thursday: The Good, The Bad And The Ugly
The good: mRNA gets its first flu approval. The bad: post-market commitments, a split pathway and a recommending committee that cannot meet. The ugly: an executive order to break up the MMR shot with no licensed products to replace it.
